ARTICLE | Clinical News
Signifor LAR pasireotide regulatory update
February 17, 2014 8:00 AM UTC
Novartis disclosed in its 4Q13 earnings that it submitted regulatory applications in the U.S. and EU for Signifor LAR pasireotide to treat patients with acromegaly for whom medical therapy is appropri...